PharmaKnowl Consulting proudly participated as an exhibitor at the World Drug Safety Congress Europe 2025, held on 7–8 October 2025 at the RAI Amsterdam, Netherlands.

Throughout the two-day congress, our team welcomed visitors and engaged with pharmacovigilance professionals, regulatory authorities, pharmaceutical and biotechnology companies, and industry partners from around the world. The event provided an excellent opportunity to exchange knowledge, discuss emerging regulatory trends, and build meaningful relationships within the global drug safety community.

As one of the world’s leading conferences dedicated to pharmacovigilance, drug safety, and risk management, the World Drug Safety Congress featured expert discussions on signal detection, benefit-risk assessment, artificial intelligence in pharmacovigilance, regulatory compliance, real-world evidence, and innovative approaches to improving patient safety across the product lifecycle.

During the exhibition, PharmaKnowl showcased its comprehensive pharmacovigilance and regulatory consulting services, including pharmacovigilance system setup and management, signal detection and risk assessment, aggregate reporting, regulatory strategy, and support for companies seeking to meet the requirements of SFDA, EMA, and other international regulators. Our team also highlighted PharmaKnowl’s expertise in helping global organizations successfully navigate regulatory pathways in Saudi Arabia and the GCC through practical, compliant, and locally focused solutions.

The congress provided valuable opportunities to strengthen existing partnerships, establish new collaborations, and stay informed on the latest developments, shaping the future of global drug safety and pharmacovigilance.

Our participation at the World Drug Safety Congress Europe 2025 reflects PharmaKnowl Consulting’s continued commitment to supporting the global life sciences industry through regulatory excellence, international collaboration, and innovative pharmacovigilance solutions that contribute to safer medicines and better patient outcomes.